• 1. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 2. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 3. Excellent energy storage performance in NaNbO3-based relaxor antiferroeic ceramics under a low electric field
  XuxinCheng,XiaomingChen,PengyuanFan
• 4. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 5. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207

Professional Introduction to 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile (CAS No. 1491181-11-3)

4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile, with the chemical identifier CAS No. 1491181-11-3, is a significant compound in the field of pharmaceutical chemistry and medicinal research. This molecule, characterized by its 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile structure, has garnered attention due to its potential applications in the development of novel therapeutic agents. The presence of both chloro and nitrile functional groups makes it a versatile intermediate for synthetic chemistry, enabling the construction of more complex molecules with desired biological activities.

The compound's pyrimidine core is a common motif in many bioactive molecules, particularly those targeting nucleic acid interactions and enzyme inhibition. Pyrimidine derivatives are well-known for their role in modulating various biological pathways, making them invaluable in drug discovery. The specific substitution pattern in 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile imparts unique electronic and steric properties that can be exploited to fine-tune its interaction with biological targets.

Recent advancements in medicinal chemistry have highlighted the importance of heterocyclic compounds like pyrimidine derivatives in addressing unmet medical needs. Studies have demonstrated that modifications at the pyrimidine ring can significantly alter the pharmacokinetic and pharmacodynamic properties of a drug candidate. The dichloro substitution at the 2 and 6 positions enhances the electrophilicity of the ring, making it more reactive in nucleophilic substitution reactions. This reactivity is leveraged in multi-step synthetic routes to introduce additional functional groups or linkages necessary for drug development.

In the context of current research, 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile has been explored as a key intermediate in the synthesis of kinase inhibitors. Kinases are enzymes that play crucial roles in cell signaling pathways and are often implicated in diseases such as cancer. By designing molecules that selectively inhibit specific kinases, researchers aim to develop targeted therapies with improved efficacy and reduced side effects. The benzonitrile moiety in this compound can serve as a pharmacophore, contributing to binding interactions with the active site of kinases or other therapeutic targets.

The nitrile group is particularly interesting from a chemical perspective. It can participate in various reactions, including hydrolysis to form carboxylic acids or reduction to form amides. These transformations are often employed in medicinal chemistry to introduce polar functional groups that enhance solubility or binding affinity. Additionally, the nitrile group can act as a leaving group in nucleophilic substitution reactions, allowing for further derivatization of the molecule.

One of the most compelling aspects of 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile is its potential as a building block for libraries of compounds in high-throughput screening (HTS) campaigns. HTS is a widely used technique for identifying lead compounds with desirable biological activity. By synthesizing libraries containing variations of this core structure, researchers can rapidly screen for molecules that exhibit target-specific interactions. This approach has been instrumental in identifying novel drugs that would otherwise remain undiscovered through traditional discovery methods.

The synthesis of 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile typically involves multi-step organic reactions starting from commercially available precursors. The process often begins with the preparation of a halogenated pyrimidine derivative followed by benzoylation to introduce the nitrile group. The chloro substituents can be introduced through halogenation reactions using reagents such as phosphorus oxychloride or sulfuryl chloride. Each step requires careful optimization to ensure high yield and purity, which are critical for subsequent applications in drug development.

The compound's stability under various conditions is another important consideration. Pyrimidine derivatives can be sensitive to moisture and light, necessitating storage under inert atmospheres to prevent degradation. Furthermore, their reactivity with certain reagents must be carefully controlled to avoid unwanted side products. Researchers must balance efficiency with selectivity to achieve the desired molecular architecture without compromising quality.

In recent years, computational methods have been increasingly employed to aid in the design and optimization of molecules like 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile. Molecular modeling techniques allow researchers to predict how a compound will interact with biological targets based on its three-dimensional structure. These predictions can guide synthetic efforts by identifying which functional groups are likely to be important for binding affinity and selectivity. Additionally, virtual screening methods can be used to rapidly sift through large databases of compounds and identify promising candidates for further investigation.

The integration of experimental data with computational predictions has led to more efficient drug discovery pipelines. By leveraging both approaches, researchers can accelerate the identification and optimization of lead compounds significantly reducing the time and cost associated with bringing new drugs to market. This synergy between experimental chemistry and computational science is particularly relevant for complex molecules like those derived from 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile.

Future directions in the study of this compound may include exploring its role in developing treatments for infectious diseases or neurological disorders. The pyrimidine scaffold is present in many antiviral and antitumor agents due to its ability to mimic natural nucleobases and interfere with nucleic acid synthesis or function. By further investigating the biological activity of derivatives like 4-(2,6-Dichloro-4-pyrimidinyl)Benzonitrile researchers may uncover new therapeutic opportunities.

In conclusion 4-(2 6-Dichloro-4-pyrimidinyl)Benzonitrile (CAS No 1491181-11-3) represents an exciting area of research within pharmaceutical chemistry Its unique structural features make it a valuable intermediate for synthesizing bioactive molecules particularly those targeting kinases or other enzymes involved in disease pathways As our understanding of molecular interactions continues to grow so too will our ability to harness this compound's potential for developing novel treatments that improve human health

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)